These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34322292)

  • 1. Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis.
    Karadag FK; Yenerel MN; Yılmaz M; Uskudar H; Ozkocaman V; Tuglular TF; Erdem F; Unal A; Ayyildiz O; Ozet G; Comert M; Kaya E; Ayer M; Salim O; Guvenc B; Ozdogu H; Mehtap Ö; Sonmez M; Guler N; Hacioglu S; Aydogdu İ; Bektas O; Toprak SK; Kaynar L; Yagci M; Aksu S; Tombak A; Karakus V; Yavasoglu İ; Onec B; Ozcan MA; Undar L; Ali R; Ilhan O; Saydam G; Sahin F
    Am J Blood Res; 2021; 11(3):279-285. PubMed ID: 34322292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
    Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
    Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
    Wang LY; Hu QL; Chen M; Yang C; Han B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
    Kim JS; Lee JW; Kim BK; Lee JH; Chung J
    Korean J Hematol; 2010 Dec; 45(4):269-74. PubMed ID: 21253430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
    Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
    J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience.
    Goren Sahin D; Akay OM; Keklik M; Okan V; Karakus A; Demir C; Erkurt MA; Ilkkilic K; Yildirim R; Akgun Cagliyan G; Aksu S; Dogu MH; Dal MS; Karakus V; Gemici AI; Terzi H; Kelkitli E; Sivgin S; Unal A; Yilmaz M; Ayyildiz O; Korkmaz S; Eser B; Altuntas F
    Ann Hematol; 2021 Jul; 100(7):1667-1675. PubMed ID: 33988739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
    Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
    Plessier A; Esposito-Farèse M; Baiges A; Shukla A; Garcia Pagan JC; De Raucourt E; Ollivier-Hourmand I; Cervoni JP; De Ledinghen V; Tazi Z; Nousbaum JB; Bun R; Bureau C; Silvain C; Tournilhac O; Gerfaud-Valentin M; Durand F; Goria O; Tellez L; Albillos A; Gioia S; Riggio O; De Gottardi A; Payance A; Rautou PE; Terriou L; Charbonnier A; Elkrief L; de la Tour RP; Valla DC; Gault N; de Fontbrune FS
    Am J Hematol; 2022 Apr; 97(4):431-439. PubMed ID: 35049058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
    Schrezenmeier H; Röth A; Araten DJ; Kanakura Y; Larratt L; Shammo JM; Wilson A; Shayan G; Maciejewski JP
    Ann Hematol; 2020 Jul; 99(7):1505-1514. PubMed ID: 32390114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience.
    Dal MS; Karakuş A; Ekmen MÖ; Ayyildiz O
    Hematol Rep; 2016 Mar; 8(1):6409. PubMed ID: 27103981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation.
    Wang HC; Kuo CY; Liu IT; Chen TY; Chang YH; Lin SJ; Cho SF; Liu YC; Liu TC; Lin SF; Chang CS
    Kaohsiung J Med Sci; 2017 Aug; 33(8):405-410. PubMed ID: 28811010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
    Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
    Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study.
    Chatzileontiadou S; Hatjiharissi E; Angelopoulou M; Asimakopoulos JV; Loutsidi NE; Chatzikonstantinou T; Zikos P; Bouchla A; Bezirgiannidou Z; Kouvata E; Frouzaki C; Chaloudis P; Sotiropoulos D; Douka V; Sirigou A; Mandala E; Psyllaki M; Papadaki HA; Marinakis T; Viniou NA; Kokkori S; Kontopidou F; Skepetari A; Vassilopoulos G; Kotsianidis I; Pappa V; Lalayanni C; Baltadakis I; Delimpassi S; Pagoni M; Papaioannou M
    Front Oncol; 2023; 13():1128994. PubMed ID: 36959785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria.
    Kulasekararaj AG; Brodsky RA; Nishimura JI; Patriquin CJ; Schrezenmeier H
    Ther Adv Hematol; 2022; 13():20406207221091046. PubMed ID: 35663504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort.
    Choi CW; Jang JH; Kim JS; Jo DY; Lee JH; Kim SH; Kim YK; Won JH; Chung JS; Kim H; Lee JH; Kim MK; Eom HS; Hyun SY; Kim JA; Lee JW
    Blood Res; 2017 Sep; 52(3):207-211. PubMed ID: 29043236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation.
    Alashkar F; Saner FH; Vance C; Schmücker U; Herich-Terhürne D; Dührsen U; Köninger A; Röth A
    Front Med (Lausanne); 2020; 7():543372. PubMed ID: 33102497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes.
    Schaap CCM; Heubel-Moenen FCJI; Nur E; Bartels M; van der Heijden OWH; de Jonge E; Preijers FWMB; Blijlevens NMA; Langemeijer SMC;
    Eur J Haematol; 2023 Jun; 110(6):648-658. PubMed ID: 36811247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.